Kymera Therapeutics, Inc. (KYMR) CEO Nello Mainolfi on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/10/22
Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/09/22
Analysts Estimate Kymera Therapeutics, Inc. (KYMR) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 08/02/22
Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh MorganGlobeNewsWire • 07/08/22
Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413PRNewsWire • 06/15/22
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell LymphomaGlobeNewsWire • 06/01/22
Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid ArthritisGlobeNewsWire • 06/01/22
Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual MeetingGlobeNewsWire • 05/20/22
Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 InflammationGlobeNewsWire • 05/05/22
Kymera Therapeutics, Inc. (KYMR) CEO Nello Mainolfi on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/03/22
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/03/22
Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/03/22
Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor ConferencesGlobeNewsWire • 04/19/22
Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022GlobeNewsWire • 04/08/22
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 02/24/22
Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business UpdateGlobeNewsWire • 02/24/22
Kymera Therapeutics to Participate in Upcoming January and February Investor ConferencesGlobeNewsWire • 01/25/22
Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of DirectorsGlobeNewsWire • 01/18/22